UF expert answers questions about the newly approved RSV vaccine
On May 3, the FDA approved a vaccine to prevent respiratory syncytial virus in older adults. Dr. Cindy Prins answers some common questions about RSV disease and the new vaccine.
On May 3, the FDA approved a vaccine to prevent respiratory syncytial virus in older adults. Dr. Cindy Prins answers some common questions about RSV disease and the new vaccine.
COVID-19 has disproportionately affected people who experience incarceration in state or federal run correctional facilities. To mitigate transmission and disease burden, US state and federal Departments of Correction (DOCs) implemented vaccine programs in the winter of 2020–2021. However, vaccine hesitancy is common among incarcerated populations due to distrust of the medical community and uncertainty around vaccine effectiveness.
UF biostatistician Ira Longini offers an expert opinion in The Lancet, along with colleagues, on the role of vaccination in reducing monkeypox viral evolution.
Recent work contributed to by UF mathematician Burton Singer seeks to estimate how COVID-19 vaccination campaigns will affect the future trajectory of the pandemic in the US.
Two new studies advance a potentially groundbreaking transmission-blocking malaria vaccine. UF researcher Rhoel Dinglasan's approach is completely different: Immunizing mosquitoes with malaria transmission-blocking antibodies produced in people.
UF investigators participate in the first study to determine that the CoronaVac vaccine is 50% effective at preventing COVID-19 in Manaus, Brazil where the P.1 variant is widespread.
A malaria vaccine designed by UF professor Rhoel Dinglasan is expected to advance to phase 1 clinical trials, thanks to new funding. The vaccine is designed differently from all others: It immunizes mosquitoes via people.
UF researchers contributed to a clinical trial that found using one-fifth of a standard dose of yellow fever vaccine is an effective strategy for emergency outbreak scenarios.
New modeling by EPI researcher Burton Singer calculates that the substantial costs involved in developing a universal flu vaccine are worth every cent. Singer collaborated with a team from Yale University, University of Texas at Austin, and the University of Maryland to calculate that a universal flu vaccine would save $3.5 billion in direct medical costs annually and save 19,500 lives in the U.S. alone.
EPI investigator, and College of Liberal Arts and Sciences mathematics professor, Burton Singer has developed a model describing the spatial dynamics of Ebola transmission and the efficacy of its vaccine.